Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.

Saved in:
Bibliographic Details
Title: Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study.
Authors: Blakely CM; Department of Medicine, University of California, San Francisco, San Francisco, CA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Urisman A; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.; Department of Pathology, University of California, San Francisco, San Francisco, CA., Gubens MA; Department of Medicine, University of California, San Francisco, San Francisco, CA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Mulvey CK; Department of Medicine, University of California, San Francisco, San Francisco, CA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Allen GM; Department of Medicine, University of California, San Francisco, San Francisco, CA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Shiboski SC; Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA., Rotow JK; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA., Chakrabarti T; Department of Medicine, University of California, San Francisco, San Francisco, CA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Kerr DL; Department of Medicine, University of California, San Francisco, San Francisco, CA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Aredo JV; Department of Medicine, University of California, San Francisco, San Francisco, CA., Bacaltos B; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Gee M; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Tan L; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA., Jones KD; Department of Pathology, University of California, San Francisco, San Francisco, CA., Devine WP; Department of Pathology, University of California, San Francisco, San Francisco, CA.; Institute for Human Genetics, University of California, San Francisco, San Francisco, CA., Doebele RC; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO., Aisner DL; Department of Pathology, University of Colorado Anschutz Medical Campus, Aurora, CO., Patil T; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO., Schenk EL; Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO., Bivona TG; Department of Medicine, University of California, San Francisco, San Francisco, CA.; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.; Chan Zuckerberg Biohub, San Francisco, CA., Riess JW; Department of Medicine, University of California Davis, Sacramento, CA., Coleman M; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.; Department of Surgery, University of California, San Francisco, San Francisco, CA., Kratz JR; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.; Department of Surgery, University of California, San Francisco, San Francisco, CA., Jablons DM; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.; Department of Surgery, University of California, San Francisco, San Francisco, CA.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Sep 10; Vol. 42 (26), pp. 3105-3114. Date of Electronic Publication: 2024 Jul 19.
Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1527-7755
DOI:10.1200/JCO.24.00071